New York lupus clinical research study now recruiting patients
If you or a loved one suffers from lupus, by taking part in a clinical trial you can play a more active role in your own health care, gain access to new investigational medications and participate in the process that evaluates potential new therapies.
Resolve Therapeutics is a biopharmaceutical company that is evaluating a potential new drug called RSLV-132. RSLV-132 is a drug that is referred to as a targeted therapy because it specifically targets molecules that are believed to be an important part of the inflammation process in lupus. The goal of a targeted therapy in lupus is to impact specific causes of inflammation while leaving the immune system intact to perform its normal function. If this goal is met, improvement in the severity of disease may be seen with fewer side effects.
Two clinical research studies to assess the safety of the drug have been successfully completed to date. We are currently conducting another clinical research study in lupus patients with an active skin rash. Please call us at 888-391-7570 to find out if this study is right for you.
To learn more about the clinical trial, call 888-391-7570
If you live close to one of these 12 leading rheumatology clinical study sites and would like to learn more about the clinical trial, please call the toll-free number above and a Resolve Therapeutics representative will be happy to speak with you to answer questions and provide more information.